Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,191
Next Earnings Date10/31/2019 (Estimated)
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Thursday, August, 1st. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.09. The business had revenue of $178 million for the quarter, compared to the consensus estimate of $171.97 million. Akorn had a negative return on equity of 17.88% and a negative net margin of 72.25%. The business's revenue for the quarter was down 6.8% on a year-over-year basis. View Akorn's Earnings History.
When is Akorn's next earnings date?
What guidance has Akorn issued on next quarter's earnings?
Akorn issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $692.99 million.
What price target have analysts set for AKRX?
4 brokerages have issued 12-month price objectives for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they expect Akorn's stock price to reach $7.00 in the next year. This suggests a possible upside of 73.5% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
Press coverage about AKRX stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akorn earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Akorn.
Are investors shorting Akorn?
Akorn saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 10,920,000 shares, a decline of 13.0% from the August 30th total of 12,550,000 shares. Based on an average trading volume of 1,920,000 shares, the short-interest ratio is presently 5.7 days. Currently, 11.6% of the company's stock are short sold. View Akorn's Current Options Chain.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Intercept Pharmaceuticals (ICPT), Xencor (XNCR), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Akcea Therapeutics (AKCA), Prestige Consumer Healthcare (PBH), Deciphera Pharmaceuticals (DCPH), Corcept Therapeutics (CORT), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Alder Biopharmaceuticals (ALDR), Pacira Biosciences (PCRX) and Insmed (INSM).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.
Which institutional investors are buying Akorn stock?
AKRX stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $4.04.
How big of a company is Akorn?
Akorn has a market capitalization of $507.80 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
